Adimmune Corp (TW:4142) — Stock Price

NT$17.55 TWD
▼ -0.85% today

Adimmune Corp (TW:4142) is currently trading at NT$17.55 TWD, down 0.85% today. Over the past 52 weeks, shares have ranged between NT$16.55 and NT$21.55. This page tracks Adimmune Corp's live share price on the TW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 4142 market cap overview.

Adimmune Corp (4142) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Adimmune Corp's daily closing share price and trading volume on the TW exchange over the past year, giving a clear view of recent price momentum and liquidity.

Adimmune Corp Income Statement — Revenue, Profit & Earnings by Year

Adimmune Corp's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20242023202220212020
Total Revenue NT$1.56 Billion NT$1.79 Billion NT$2.25 Billion NT$1.64 Billion NT$1.87 Billion
Cost of Revenue NT$1.11 Billion NT$1.37 Billion NT$1.36 Billion NT$1.18 Billion NT$1.25 Billion
Gross Profit NT$448.06 Million NT$410.94 Million NT$891.08 Million NT$464.14 Million NT$623.06 Million
Research & Development NT$292.05 Million NT$296.93 Million NT$346.42 Million NT$321.28 Million NT$337.68 Million
SG&A NT$294.96 Million NT$313.24 Million NT$295.32 Million NT$304.26 Million NT$281.90 Million
Total Operating Expenses NT$747.15 Million NT$1.13 Billion NT$792.53 Million NT$670.95 Million NT$648.88 Million
Operating Income NT$-299.09 Million NT$-722.75 Million NT$98.55 Million NT$-54.09 Million NT$-25.81 Million
EBITDA NT$-84.30 Million NT$-512.43 Million NT$438.12 Million NT$254.89 Million NT$1.45 Billion
EBIT NT$-300.00 Million NT$-736.55 Million NT$178.81 Million NT$28.97 Million NT$1.22 Billion
Interest Expense NT$36.49 Million NT$33.43 Million NT$22.59 Million NT$14.69 Million NT$22.16 Million
Income Before Tax NT$-336.49 Million NT$-769.98 Million NT$156.22 Million NT$14.29 Million NT$1.20 Billion
Income Tax Expense NT$380.07 Million NT$10.00 Million NT$-14.09 Million NT$-21.82 Million
Net Income NT$-242.75 Million NT$-639.89 Million NT$290.98 Million NT$43.07 Million NT$1.24 Billion

Adimmune Corp Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Adimmune Corp's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20242023202220212020
Total Assets NT$8.48 Billion NT$9.48 Billion NT$9.15 Billion NT$8.01 Billion NT$8.47 Billion
Total Current Assets NT$3.61 Billion NT$4.70 Billion NT$4.49 Billion NT$3.80 Billion NT$5.05 Billion
Cash & Equivalents
Short-term Investments NT$127.51 Million NT$27.51 Million NT$115.51 Million NT$239.00 Million NT$349.56 Million
Net Receivables NT$187.81 Million NT$1.31 Billion NT$534.97 Million NT$99.64 Million NT$109.75 Million
Inventory NT$627.99 Million NT$526.41 Million NT$659.33 Million NT$505.88 Million NT$302.05 Million
Property, Plant & Equipment NT$3.45 Billion NT$2.35 Billion
Goodwill NT$19.36 Million NT$25.32 Million NT$31.27 Million NT$37.23 Million
Total Liabilities NT$2.92 Billion NT$3.71 Billion NT$2.60 Billion NT$1.58 Billion NT$1.84 Billion
Total Current Liabilities NT$1.16 Billion NT$1.79 Billion NT$500.49 Million NT$297.04 Million NT$525.41 Million
Long-term Debt NT$1.71 Billion NT$1.87 Billion NT$2.04 Billion NT$1.27 Billion NT$1.31 Billion
Net Debt NT$252.12 Million NT$685.13 Million NT$-594.50 Million NT$-1.33 Billion NT$-2.77 Billion
Total Stockholder Equity NT$5.23 Billion NT$5.47 Billion NT$6.12 Billion NT$6.15 Billion NT$6.32 Billion
Retained Earnings NT$205.41 Million NT$451.83 Million NT$1.12 Billion NT$832.55 Million NT$1.12 Billion

Adimmune Corp Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Adimmune Corp generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20242023202220212020
Operating Cash Flow NT$668.48 Million NT$-892.35 Million NT$-291.96 Million NT$-480.52 Million NT$2.32 Billion
Capital Expenditures NT$155.22 Million NT$221.46 Million NT$419.62 Million NT$845.26 Million NT$218.30 Million
Free Cash Flow NT$513.26 Million NT$-1.11 Billion NT$-711.59 Million NT$-1.33 Billion NT$2.10 Billion
Investing Cash Flow NT$-310.90 Million NT$-366.56 Million NT$-322.07 Million NT$-728.84 Million NT$382.76 Million
Financing Cash Flow NT$-478.80 Million NT$859.30 Million NT$823.19 Million NT$-222.89 Million NT$323.88 Million
Dividends Paid NT$214.75 Million NT$214.75 Million
Stock-Based Compensation NT$24.57 Million NT$21.62 Million NT$16.01 Million NT$25.17 Million NT$13.85 Million
Depreciation NT$215.70 Million NT$224.12 Million NT$259.32 Million NT$225.91 Million NT$227.58 Million
Change in Cash NT$-112.88 Million NT$-399.58 Million NT$205.07 Million NT$-1.44 Billion NT$3.03 Billion

Adimmune Corp Earnings History — EPS Actual vs. Analyst Estimates

Track Adimmune Corp's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Nov 11, 2025
Aug 11, 2025
May 14, 2025 -0.53 -0.65 +18.46%
Mar 12, 2025 -0.12 0.21 -157.14%
Nov 12, 2024
Mar 13, 2024 -0.98
Nov 12, 2023 0.62 0.67 -7.46%
Aug 11, 2023 -0.57 -0.09 -533.33%